Prevail Therapeutics to Present at Upcoming Investor Conferences
Prevail Therapeutics (Nasdaq: PRVL) announced participation in upcoming virtual investor conferences, featuring CEO Asa Abeliovich.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Prevail Therapeutics (Nasdaq: PRVL) announced participation in upcoming virtual investor conferences, featuring CEO Asa Abeliovich. The events include the Guggenheim Healthcare Talks on November 16, 2020, the Stifel 2020 Virtual Healthcare Conference on November 18, 2020, and the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1, 2020. Webcasts of the presentations will be accessible on their website. Prevail focuses on developing AAV-based gene therapies for neurodegenerative diseases, with key products in development for Parkinson’s disease and frontotemporal dementia.
Details
News Market Reaction – PRVL
The recorded move for PRVL in the trading session of this news was +3.01%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of Prevail, will participate in the following virtual investor conferences in November and December:
- Guggenheim Healthcare Talks Idea Forum 2nd Annual Neuro/Immunology Day on Monday, November 16, 2020.
- Stifel 2020 Virtual Healthcare Conference on Wednesday, November 18, 2020 at 10:40-11:10 a.m. ET.
- Piper Sandler 32nd Annual Virtual Health Care Conference on Tuesday, December 1, 2020.
Webcasts of the presentations will be available under "Events and Presentations" in the Investors and Media section of the Company's website at ir.prevailtherapeutics.com following the presentations.
About Prevail Therapeutics
Prevail is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The Company is developing PR001 for patients with Parkinson’s disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease (nGD); PR006 for patients with frontotemporal dementia with GRN mutations (FTD-GRN); and PR004 for patients with certain synucleinopathies.
Prevail was founded by Dr. Asa Abeliovich in 2017, through a collaborative effort with The Silverstein Foundation for Parkinson’s with GBA and OrbiMed, and is headquartered in New York, NY.
Media Contact:
Lisa Qu
Ten Bridge Communications
LQu@tenbridgecommunications.com
678-662-9166
Investor Contact:
investors@prevailtherapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.